Trimetrexate: a critical appraisal of the phase II clinical trial experience: evidence of drug discovery-clinical development disjunction.
Seitz
D E
DE
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285.
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D000882:Haplorhini; D006801:Humans; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D016597:Trimetrexate / Q000627:therapeutic use*
D016597:Trimetrexate